Twitter

Kalqyl in new analysis of Chordate: “Increased foothold in the market”

Kalqyl has today, April 3rd, published an updated analysis of Chordate Medical following the company’s year-end report, which was released on March 22. In the analysis, Kalqyl comments on, among other things, Chordate’s positive sales trend and breakthrough in Germany.

“We expect that the positive sales trend will continue throughout 2024, primarily driven by a gradually increasing utilization rate of the treatment system, broader marketing of the study results from PM007, and breakthrough in the German market. Chordate’s report for the fourth quarter showed that the company took continued steps in all parts of the marketing plan, which ultimately should enable a sale of the company,” writes Kalqyl.

Read the full analysis here

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter